

AMENDMENT

U.S. Appln. No. 09/915,543

IN THE CLAIMS:

Please enter the following cancellations, amendments and/or additions:

Claims 1-70. (Cancelled).

Claim 71. (New) An isolated polypeptide comprising:

(i) a peptide consisting of amino acids 177 to 204 of SEQ ID NO:15, or a peptide having at least 90% amino acid sequence identity to said (i), or

(ii) a peptide consisting of amino acids 349 to 383 of SEQ ID NO:15, or a peptide having at least 90% amino acid sequence identity to said (ii),

wherein said isolated polypeptide blocks Lgs function in colon cancer cells.

Claim 72. (New) An isolated polypeptide comprising:

(i) a peptide consisting of amino acids 199 to 392 of SEQ ID NO:15, or

(ii) a peptide having at least 90% amino acid sequence identity to (i), wherein said isolated polypeptide blocks Lgs function in colon cancer cells, or

(iii) a fragment of (i) or (ii), wherein said fragment comprises a binding site for an anti-Bcl9/hLgs antibody,

wherein said isolated polypeptide blocks Lgs function in colon cancer cells.

Claim 73. (New) A chimeric molecule comprising the polypeptide of Claim 71 fused to a heterologous polypeptide.

AMENDMENT

U.S. Appln. No. 09/915,543

Claim 74. (New) A chimeric molecule comprising the polypeptide of Claim 72 fused to a heterologous polypeptide.

Claim 75. (New) The chimeric molecule according to Claim 74, wherein said heterologous polypeptide is selected from the group consisting of an antigenic epitope, glutathione-S-transferase, thioredoxin, and antibody.

Claim 76. (New) The chimeric molecule according to Claim 74, wherein said heterologous polypeptide is selected from the group consisting of an antigenic epitope, glutathione-S-transferase, thioredoxin, and antibody.

Claim 77. (New) A pharmaceutical composition comprising the polypeptide of Claim 71, and a pharmaceutically acceptable carrier.

Claim 78. (New) A pharmaceutical composition comprising the polypeptide of Claim 72, and a pharmaceutically acceptable carrier.